MedTrace Logo

Hs-Troponin T Kinetics in Patients Treated With MCO Membranes Compared to High-flux, Low-flux Membranes and HDF

NCT05439681 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2023-03-02

No results posted yet for this study

Summary

In this study, 24 prevalent hemodialysis patients will undergo four regular hemodialysis sessions during which four different treatments will be performed.

* Treatment 1: MCO membrane (=medium cut off)
* Treatment 2: low flux membrane
* Treatment 3: high flux membrane
* Treatment 4: HDF(=hemodiafiltration) treatment with high flux membrane

So far, there is no data on cardiac bioenzyme levels during hemodialysis on the MCO membrane, thus, a acute elevation during hemodialysis might be mitigated by increased clearance.

Conditions

  • Troponin T

Interventions

DEVICE

Theranova 400

medium cut off (MCO) membrane

DEVICE

FX 10

low-flux membrane

DEVICE

FX CorDiax 800

high-flux membrane

DEVICE

HDF

hemodiafiltration

Sponsors & Collaborators

  • Medical University of Graz

    lead OTHER

Principal Investigators

  • Alexander H Kirsch, MD · Medical University of Graz

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-12
Primary Completion
2022-12-24
Completion
2022-12-24

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05439681 on ClinicalTrials.gov